Cargando…

Efficacy for Whitlockite for Augmenting Spinal Fusion

Whitlockite (WH) is the second most abundant inorganic component of human bone, accounting for approximately 25% of bone tissue. This study investigated the role of WH in bone remodeling and formation in a mouse spinal fusion model. Specifically, morphology and composition analysis, tests of porosit...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Su Yeon, Shim, Jung Hee, Kim, Yu Ha, Lim, Chang Su, An, Seong Bae, Han, Inbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657587/
https://www.ncbi.nlm.nih.gov/pubmed/34884680
http://dx.doi.org/10.3390/ijms222312875
_version_ 1784612534233333760
author Kwon, Su Yeon
Shim, Jung Hee
Kim, Yu Ha
Lim, Chang Su
An, Seong Bae
Han, Inbo
author_facet Kwon, Su Yeon
Shim, Jung Hee
Kim, Yu Ha
Lim, Chang Su
An, Seong Bae
Han, Inbo
author_sort Kwon, Su Yeon
collection PubMed
description Whitlockite (WH) is the second most abundant inorganic component of human bone, accounting for approximately 25% of bone tissue. This study investigated the role of WH in bone remodeling and formation in a mouse spinal fusion model. Specifically, morphology and composition analysis, tests of porosity and surface area, thermogravimetric analysis, an ion-release test, and a cell viability test were conducted to analyze the properties of bone substitutes. The MagOss group received WH, Group A received 100% beta-tricalcium phosphate (β-TCP), Group B received 100% hydroxyapatite (HAp), Group C received 30% HAp/70% β-TCP, and Group D received 60% HAp/40% β-TCP (n = 10 each). All mice were sacrificed 6 weeks after implantation, and micro-CT, hematoxylin and eosin (HE) staining, and Masson trichome (MT) staining and immunohistochemistry were performed. The MagOss group showed more homogeneous and smaller grains, and nanopores (<500 nm) were found in only the MagOss group. On micro-CT, the MagOss group showed larger fusion mass and better graft incorporation into the decorticate mouse spine than other groups. In the in vivo experiment with HE staining, the MagOss group showed the highest new bone area (mean: decortication group, 9.50%; A, 15.08%; B, 15.70%; C, 14.76%; D, 14.70%; MagOss, 22.69%; p < 0.0001). In MT staining, the MagOss group demonstrated the highest new bone area (mean: decortication group, 15.62%; A, 21.41%; B, 22.86%; C, 23.07%; D, 22.47%; MagOss, 26.29%; p < 0.0001). In an immunohistochemical analysis for osteocalcin, osteopontin, and CD31, the MagOss group showed a higher positive area than other groups. WH showed comparable bone conductivity to HAp and β-TCP and increased new bone formation. WH is likely to be used as an improved bone substitute with better bone conductivity than HAp and β-TCP.
format Online
Article
Text
id pubmed-8657587
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86575872021-12-10 Efficacy for Whitlockite for Augmenting Spinal Fusion Kwon, Su Yeon Shim, Jung Hee Kim, Yu Ha Lim, Chang Su An, Seong Bae Han, Inbo Int J Mol Sci Article Whitlockite (WH) is the second most abundant inorganic component of human bone, accounting for approximately 25% of bone tissue. This study investigated the role of WH in bone remodeling and formation in a mouse spinal fusion model. Specifically, morphology and composition analysis, tests of porosity and surface area, thermogravimetric analysis, an ion-release test, and a cell viability test were conducted to analyze the properties of bone substitutes. The MagOss group received WH, Group A received 100% beta-tricalcium phosphate (β-TCP), Group B received 100% hydroxyapatite (HAp), Group C received 30% HAp/70% β-TCP, and Group D received 60% HAp/40% β-TCP (n = 10 each). All mice were sacrificed 6 weeks after implantation, and micro-CT, hematoxylin and eosin (HE) staining, and Masson trichome (MT) staining and immunohistochemistry were performed. The MagOss group showed more homogeneous and smaller grains, and nanopores (<500 nm) were found in only the MagOss group. On micro-CT, the MagOss group showed larger fusion mass and better graft incorporation into the decorticate mouse spine than other groups. In the in vivo experiment with HE staining, the MagOss group showed the highest new bone area (mean: decortication group, 9.50%; A, 15.08%; B, 15.70%; C, 14.76%; D, 14.70%; MagOss, 22.69%; p < 0.0001). In MT staining, the MagOss group demonstrated the highest new bone area (mean: decortication group, 15.62%; A, 21.41%; B, 22.86%; C, 23.07%; D, 22.47%; MagOss, 26.29%; p < 0.0001). In an immunohistochemical analysis for osteocalcin, osteopontin, and CD31, the MagOss group showed a higher positive area than other groups. WH showed comparable bone conductivity to HAp and β-TCP and increased new bone formation. WH is likely to be used as an improved bone substitute with better bone conductivity than HAp and β-TCP. MDPI 2021-11-28 /pmc/articles/PMC8657587/ /pubmed/34884680 http://dx.doi.org/10.3390/ijms222312875 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kwon, Su Yeon
Shim, Jung Hee
Kim, Yu Ha
Lim, Chang Su
An, Seong Bae
Han, Inbo
Efficacy for Whitlockite for Augmenting Spinal Fusion
title Efficacy for Whitlockite for Augmenting Spinal Fusion
title_full Efficacy for Whitlockite for Augmenting Spinal Fusion
title_fullStr Efficacy for Whitlockite for Augmenting Spinal Fusion
title_full_unstemmed Efficacy for Whitlockite for Augmenting Spinal Fusion
title_short Efficacy for Whitlockite for Augmenting Spinal Fusion
title_sort efficacy for whitlockite for augmenting spinal fusion
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657587/
https://www.ncbi.nlm.nih.gov/pubmed/34884680
http://dx.doi.org/10.3390/ijms222312875
work_keys_str_mv AT kwonsuyeon efficacyforwhitlockiteforaugmentingspinalfusion
AT shimjunghee efficacyforwhitlockiteforaugmentingspinalfusion
AT kimyuha efficacyforwhitlockiteforaugmentingspinalfusion
AT limchangsu efficacyforwhitlockiteforaugmentingspinalfusion
AT anseongbae efficacyforwhitlockiteforaugmentingspinalfusion
AT haninbo efficacyforwhitlockiteforaugmentingspinalfusion